ClinicalTrials.Veeva

Menu

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

C

CKD Bio

Status and phase

Completed
Phase 1

Conditions

Glabellar Lines

Treatments

Drug: CKDB-501B
Drug: Botox®50U

Study type

Interventional

Funder types

Industry

Identifiers

NCT05428930
CKDB-BAGL-102

Details and patient eligibility

About

A single-center, randomized, double-blind, single-injection, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501B in Glabellar lines.

Enrollment

30 patients

Sex

All

Ages

19 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Subjects with at least moderate glabellar frown lines at maximum frown using the severity score of at least 2(moderate) on the Facial Wrinkle Scale (4-point FWS)

Exclusion criteria

  • Any medical condition (e.g., myasthenia gravis, Lambert-Easton syndrome, amyotrophic lateral sclerosis, etc.) that can affect the neuromuscular function
  • History of facial nerve paralysis or ptosis
  • Significant facial asymmetry
  • Subjects with skin abnormalities such as infection, dermatologic disorders, scars, etc. at potential injection sites
  • Previous treatment with any serotype of botulinum toxin products within 24 weeks (6 months) prior to Screening or planning to receive treatment with botulinum toxin during the study period
  • Previous treatment with retinoids (isotretinoin, alitretinoin, etc.)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

30 participants in 2 patient groups

CKDB-501B
Experimental group
Treatment:
Drug: CKDB-501B
Botox® 50U
Active Comparator group
Treatment:
Drug: Botox®50U

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems